Responding to the multidrug-resistant tuberculosis crisis: Mainstreaming programmatic management to the Philippine National Tuberculosis Programme

International Journal of Tuberculosis and Lung Disease

Volumn 14, Issue 6, 2010, Pages 751-757

  Quelapio, M I D ^a   Mira, N R C ^a   Orillaza Chi, R B ^a   Belen, V ^a   Munez N ^a   Belchez, R ^a   Egos, G E ^a   Evangelista, M ^a   Vianzon, R ^b   Tupasi, T E ^a  

^a Tropical Disease Foundation   (Philippines)

^b National TB Control Program   (Philippines)

Author keywords

DOTS; Multidrug resistant TB; Philippines; Private public mix (PPM); Programmatic management of drug resistant TB (PMDT); Public private partnership

Indexed keywords

AMINOSALICYLIC ACID; CYCLOSERINE; ETHIONAMIDE; ISONIAZID; PROTIONAMIDE; QUINOLONE DERIVATIVE; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CONTROLLED STUDY; CRISIS INTERVENTION; EXPLORATORY RESEARCH; GOVERNMENT; HEALTH PROGRAM; HUMAN; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALARIA; MEDICAL SERVICE; MULTIDRUG RESISTANT TUBERCULOSIS; NONHUMAN; PHILIPPINES; PRIORITY JOURNAL; PUBLIC HEALTH; TUBERCULOSIS; COMPARATIVE STUDY; DISEASE OUTBREAKS; HEALTH CARE COST; ORGANIZATION AND MANAGEMENT; OUTCOME ASSESSMENT; PROCEDURES; PROGRAM EVALUATION; RETROSPECTIVE STUDY; TUBERCULOSIS, MULTIDRUG-RESISTANT;

ANTITUBERCULAR AGENTS; DISEASE OUTBREAKS; HEALTH CARE SECTOR; HUMANS; OUTCOME ASSESSMENT (HEALTH CARE); PHILIPPINES; PROGRAM EVALUATION; RETROSPECTIVE STUDIES; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 77952364408     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. World Health Organization. Global tuberculosis control 2009: epidemiology, strategy, financing. WHO report 2009. WHO/HTM/TB/2009.411. Geneva, Switzerland: WHO, 2009.
2. Tupasi T E, Radhakrishna S, Co V M, et al. Bacillary disease and health seeking behavior among Filipinos with symptoms of tuberculosis: implications for control. Int J Tuberc Lung Dis 2000; 4: 1126-1132. (Pubitemid 32046290)
3. World Health Organization. Treatment of tuberculosis: guidelines for national programmes. 2nd ed. WHO/TB/97.220. Geneva, Switzerland: WHO, 1997.
4. Quelapio M I D, Mira N R C, Tupasi T E, et al. Directly observed therapy-short course (DOTS) at the Makati Medical Center. Phil J Microbiol Infect Dis 2000; 29: 80-86.
5. Quelapio M I D, Orillaza R B, Tupasi T E, et al. Contribution of a PPMD clinic to case detection in its catchment area. Int J Tuberc Lung Dis 2005; 9 (Suppl 1): S68.
6. Western Pacific Office, World Health Organization. WHO external evaluation of public-private mix DOTS supported by the GFATM in the Philippines, 17-21 January 2005. Manila, the Philippines: WHO, 2005.
7. Voniatis M N, Nievera L, Lagahid J Y, Vianzon R G, Sarmiento A S, Yu C. Public-private mix DOTS (PPMD): a successful strategy in engaging health care providers and increasing access. Int J Tuberc Lung Dis 2008; 12 (Suppl): S289.
8. Tupasi T E, Gupta R, Quelapio M I, Floyd K, et al. Feasibility and cost-effectiveness of treating multidrug-resistant tuberculosis: a cohort study in the Philippines. PLoS Med 2006; 3: e352. (Pubitemid 44455269)
9. National Statistical Coordination Board. Philippine minimum national social data set. Population estimates by five-year age group and sex. Makati City, Philippines: NSCB, 2000. http://www.nscb.gov.ph/stats/mnsds/mnsds-pop.asp Accessed March 2010.
10. World Health Organization. WHO/International Union Against Tuberculosis and Lung Disease global project on anti-tuberculosis drug resistance surveillance 2002-2007. WHO/HTM/TB/2008. 394. Geneva, Switzerland: WHO, 2008.
11. Ba F, Rieder H L. A comparison of fluorescence microscopy with the Ziehl-Neelsen technique in the examination of sputum for acid-fast bacilli. Int J Tuberc Lung Dis 1999; 3: 1101-1105.
12. Kent P T, Kubica G P. Public health mycobacteriology: a guide for the level III laboratory. Atlanta, Georgia, USA: Centers for Disease Control and Prevention, 1985: pp 71-120.
13. Canetti G, Fox W. Khomenko A, et al. Advances in techniques of testing mycobacterial drug sensitivity, and the use of sensitivity tests in tuberculosis control programmes. Bull World Health Organ 1969; 41: 21-43.
14. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis. WHO/HTM/TB/2008.402. Geneva, Switzerland: WHO, 2008.
15. Concepción A A L, Quelapio M I D, Tupasi T E, et al. Case management discussions in an internal consilium. Int J Tuberc Lung Dis 2006; 10 (Suppl 1): S125.
16. Rich M L, ed. The PIH guide to the medical management of multidrug-resistant tuberculosis. International edition. Boston, MA, USA: Partners in Health, 2003.
17. Tupasi T E, Quelapio M I, Orillaza R B, et al. DOTS-Plus for multidrug-resistant tuberculosis in the Philippines: global assistance urgently needed. Tuberculosis (Edinb) 2003; 83: 52-58.
18. Quelapio M I, Chi R O, Mira N R, et al. Mainstreaming MDR-TB management to the National TB Programme in the Philippines: milestones and lessons learnt. Int J Tuberc Lung Dis 2008; 12: S303.
19. Mira N R C, Quelapio M I D, Tupasi T E, et al. Improved treatment adherence through community-based DOTS Plus. Int J Tuberc Lung Dis 2006; 10 (Suppl 1): S207.
20. Tropical Disease Foundation and Department of Health, Philippines. Management of drug-resistant tuberculosis training for health facility staff in the Philippines. Makati City, Philippines: Tropical Disease Foundation, 2008.
21. World Health Organization. Task analysis: the basis for development of training in management of tuberculosis. WHO/HTM/TB/2005.354. Geneva, Switzerland: WHO, 2005.
22. Department of Health, Philippines. Administrative Order No. 2008-0018. Guidelines for the implementation of programmatic management of drug-resistant TB. Manila, Philippines: Department of Health, 2008.
23. Concepcion A A, Quelapio M I D, Tupasi T E, et al. Operations research: managing second-line anti-tuberculosis drugs at the MDR-TB treatment site level. Int J Tuberc Lung Dis 2008; 12 (Suppl 2): S116.
24. Department of Health, Philippines. National Tuberculosis Control Program revised manual of procedures. Manila, Philippines: Department of Health, 2005.
25. Quelapio M I D, Gler T, Tupasi T E. Recording and Reporting of MDR-TB where there is a strong private sector. Int J Tuberc Lung Dis 2008; 12 (Suppl 2): S41.
26. Quelapio M I, Galipot M, Egos G, et al. Programme performance indicators in MDR-TB management in the Philippines. Int J Tuberc Lung Dis 2008; 12 (Suppl 2): S162.
27. US Centers for Disease Control and Prevention. Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs-worldwide, 2000-2004. MMWR 2006; 55: 301-305.
28. Gandhi N R, Moll A, Sturm A W, et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 2006; 368: 1575-1580. (Pubitemid 44780738)
29. World Health Organization. WHO stop TB strategy 2006. WHO/HTM/TB/2006.368. Geneva, Switzerland: WHO, 2006.
30. World Health Organization. WHO MDR-TB and XDR-TB response plan 2007-2008. WHO/HTM/STB/2007.387. Geneva, Switzerland: WHO, 2007.
31. Stop TB Partnership and World Health Organization. Global plan to stop TB, 2006-2015. WHO/HTM/STB/2006.35. Geneva, Switzerland: WHO, 2006.
32. Department of Health and Philippine Coalition against Tuberculosis. Operational guidelines for public-private mix DOTS in the Philippines. Manual of operations. Manila, Philippines: DoH and PhilCAT, 2005.
33. Shin S, Furin J, Bayona J, Mate K, Kim J Y, Farmer P. Community-based treatment of multidrug-resistant tuberculosis in Lima, Peru: 7 years of experience. Soc Sci Med 2004; 59: 1529-1539.
34. World Health Organization. Everybody's business: strengthening health systems to improve health outcomes. WHO's Framework for action. Geneva, Switzerland: WHO, 2007.